Skip to main content
NCBI home page
Stem Cells International logoLink to Stem Cells International
. 2016 Feb 24;2016:8352684. doi: 10.1155/2016/8352684

The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells

Sabrina Bimonte 1,*, Antonio Barbieri 2, Maddalena Leongito 1, Giuseppe Palma 2, Vitale del Vecchio 2, Michela Falco 2, Raffaele Palaia 1, Vittorio Albino 1, Mauro Piccirillo 1, Alfonso Amore 1, Antonella Petrillo 3, Vincenza Granata 3, Francesco Izzo 1
PMCID: PMC4783541  PMID: 27006664

Abstract

Pancreatic ductal adenocarcinoma is currently one of the deadliest cancers with low overall survival rate. This disease leads to an aggressive local invasion and early metastases and is poorly responsive to treatment with chemotherapy or chemoradiotherapy. Several studies have shown that pancreatic cancer stem cells (PCSCs) play different roles in the regulation of drug resistance and recurrence in pancreatic cancer. MicroRNA (miRNA), a class of newly emerging small noncoding RNAs, is involved in the modulation of several biological activities ranging from invasion to metastases development, as well as drug resistance of pancreatic cancer. In this review, we synthesize the latest findings on the role of miRNAs in regulating different biological properties of pancreatic cancer stem cells.

1. Introduction

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer death in the United States and the seventh worldwide, with low overall survival rate [1, 2]. Surgical resection remains the only curative therapeutic treatment for this aggressive disease, although the minority of the patients can undergo resection as consequence of tardive diagnosis [3, 4]. PDAC leads to an aggressive local invasion and early metastases, and it is noted that this disease is poorly responsive to treatment with chemotherapy or radiation therapy [5–7]. To date, gemcitabine is the best chemotherapeutic agent used for pancreatic cancer treatment, although patients showed drug resistance over the time [8–11]. In order to improve PDAC prognosis and to bypass the problem of pancreatic tumor chemoresistance, many alternative treatments have been proposed [12]. Unfortunately, the results are not very encouraging, since the overall survival of patients was not significantly improved. Emerging studies showed that cancer stem cells (CSCs) regulate several mechanisms underlying drug resistance, carcinogenesis, and metastases development in various types of cancer including pancreatic cancer, highlighting the possibility that these cells could represent valid candidates to ameliorate pancreatic cancer prognosis [13, 14].

CSCs were identified for the first time in acute myeloid leukemia [15, 16] and then in the solid tumors, including pancreatic cancer [17–19]. These cells are able to differentiate into several cancer cell types [20] and are involved in the initiation, the propagation, and the therapeutic resistance of various types of human cancer [21–25]. Pancreatic cancer stem cells (PCSCs) show the same properties of normal stem cells and can regulate pancreatic tumorigenesis. It has also been demonstrated that these cells can play several roles in the regulation of chemoresistance in pancreatic cancer [22, 26, 27], although the underlying mechanisms are not completely elucidated. Recent studies dissected the role of microRNAs (miRNAs) and PCSCs on the modulation of pancreatic cancer etiology and progression, shedding light on their importance as potential therapeutic targets for pancreatic cancer [17, 28–31]. In this review, we synthesize the latest findings on the role of miRNAs in regulating key biological properties of pancreatic cancer stem cells.

2. Characteristics of Pancreatic Cancer Stem Cells (PCSCs)

PCSCs, also named tumor-initiating pancreatic cancer stem cells, were described by Li et al. [22], through the generation of a mouse model of human pancreatic adenocarcinoma. The authors isolated these subsets of cells as CD24+CD44+ESA+ (epithelial specific antigen), which, despite accounting for less than 1% of all pancreatic cancer cells, showed a highly tumorigenic potential respect to noncarcinogenic cancer cells. Later on, many studies based on several xenograft models identified other markers for pancreatic cancer stem cells such as CD133, c-Met, ALDH1 (aldehyde dehydrogenease-1), Lgr5 (leucine-rich repeat-containing G-protein coupled receptor 5), and DclK1 (doublecortin-like kinase 1) (Figure 1) [17, 47–54], although further studies will be necessary to better define the cell surface markers of PCSCs.

Figure 1.

Figure 1

Open in a new tab

The role of cancer stem cells markers during pancreatic cancer development. The cartoon recapitulates the role of cancer stem cells markers during pancreatic cancer development and the signaling pathways involved.

3. Signaling Pathway Involved in the Regulation of Pancreatic Cancer Stem Cells (PCSCs)

The properties of PCSCs have been investigated by dissecting the underlying signaling pathways and regulatory genes such as Wnt/β catenin, Notch, c-myc, Sonic Hedgehog, and Bmi-1 [32, 47, 55, 56] (Table 1). The Hedgehog signaling (Hh) pathway plays a key regulator role in the embryonic development and patterning [33, 57] and it is activated by a complex mechanism of interaction between three Hedgehog (Hh) ligand proteins (Sonic, Indian, and Desert Hh) and cell surface receptors patched (Ptch1 and Ptch2) [13]. It is of note that Hh signaling is necessary for the PCSCs renewal and the maintenance of stemness [58–63]. Notch signaling controls pancreatic self-differentiation by acting on the self-renewal process [64]. Moreover, it has been demonstrated that Notch-1 is involved in the epithelial-mesenchymal transition (EMT) of Aspc-1 pancreatic cancer cell line [65] and in the maintenance of the cancer stem cell population [34]. These studies suggest that Notch signaling is essential for the pancreatic CSC formation. Another signaling involved in the organogenesis of the pancreas is the Wnt-β-catenin signaling pathway. It has been demonstrated that Wnt signaling is associated with EMT process in colorectal cancer [66]. Other studies proved that different pathways are involved in the maintenance of pancreatic CSCs such as NF-κB [67] and mTOR pathway [68].

Table 1.

Self-renewal pathways in PCSCs.

Signaling pathways Effects on tumorigenesis and drug resistance Targets Reference
Hedgehog Proliferation ALDH+ CD44+CD24+ESA+ [32–34]
ALK4 Invasion and metastasis CD133+ [35]
Notch Proliferation ALDH+ [34]
c-Met Drug resistance c-Met+, CD133+ [36]
Open in a new tab

Altogether, these results suggest that different signaling pathways are involved in the self-renewal and the maintenance of pancreatic cancer stem cells.

4. The Biogenesis of MicroRNAs (miRNAs)

MicroRNAs (miRNAs) are small noncoding RNAs involved in the regulation of gene expression at posttranscriptional level by binding to the 3′-untranslated regions (3′UTRs) or the open reading frames of target genes. This leads to the repression of mRNA translation or to the degradation of target mRNAs [69]. miRNAs are single-stranded, 18–25 nucleotides long. In animals, they are transcribed as long primary transcripts (pri-miRNA) by RNA polymerase II, which are processed in the nucleus by RNase III Drosha into 70–100-nucleotide-long precursor named hairpin miRNAs (pre-miRNAs) [70]. Then, pre-miRNAs are exported to the cytoplasm by Exportin-5 [71–73] and further cleaved in a complex composed of RNase III enzyme, Dicer, and the transactivating response RNA-binding protein (TRBP) into complex named miRNA:miRNA∗ [74–77]. The complementary star strand (miRNA∗) is usually degraded, even if it has been suggested that when it is not degraded, it may have some relevant biological functions [78, 79]. The other strand is chosen as a guide strand that recognizes target mRNAs on the basis of complementarity of sequence. This mature miRNA is loaded into an Argonaute protein within the RNA-induced silencing complex (RISC), which then regulates targets repression by promoting destabilization or inhibiting translation of target mRNA [80–83]. Experimental data showed that miRNAs bind to the open reading frame or to the 5′UTR [84, 85]. The biogenesis of miRNA is showed in Figure 2.

Figure 2.

Figure 2

Open in a new tab

The miRNAs biogenesis.

RNA polymerase II transcribes miRNA genes together with specific transcription factors (TF), as long primary transcripts (pri-miRNA). These transcripts are processed in the nucleus by the RNA polymerase III enzyme Drosha, in complex with DGCR8, into pre-miRNAs. These transcripts are exported into the cytoplasm by Exportin-5. Pre-miRNAs are processed by the RNase III enzyme Dicer, in complex with TRBP, into a duplex of a guide strand (miRNA) and passenger star strand (miRNA∗). The guide stand miRNA is loaded into the RISC and is able to recognize target mRNAs on the basis of sequence complementarity. The RISC regulates target repression.

5. The Regulatory Functions of miRNAs on PCSCs Properties

Many studies demonstrated that miRNAs play critical roles in the regulation of CSCs in different types of malignant tumors including pancreatic cancer and have been considered potential targets for cancer therapy, since they are involved in the initiation, the propagation, and the regulation of EMT of cancer stem cells [39, 43, 86–92]. Several miRNAs show different expression profiles in various types of cancer, including pancreatic cancer [93, 94]. Moreover, there is a difference between the miRNA complement of cancer cells and those of nontumor cells. miRNAs can be classified in two different groups based on their role on the progression of human cancer and their expression profile: (1) the oncogenic miRNAs (miR-21, miR-155, miR-17-5p, etc.) that are upregulated in tumor cells [65, 95]; (2) the tumor suppressor miRNAs (miR-34, miR-15a, miR-16-1, let-7, etc.), which are downregulated in pancreatic cancer [43, 96].

Regarding the role of oncogenic miRNAs on PCSCs properties, interesting studies provided evidence that miR-21 modulates the proliferation and the chemoresistance of pancreatic cancer cells [37, 38]. In addition, Giovannetti et al. [97] showed that there is a correlation between miR-21 expression and the clinical outcome of patients with pancreatic cancer through involvement of PI3K/AKT pathway.

On the other hand, other studies showed that upregulated expression of miR-34, which is classified as tumor suppressor miRNA and is regulated by p53, leads to the inhibition of human pancreatic cancer tumor-initiating cells, indicating that miR-34 is involved in the self-renewal process of PCSCs [43, 44].

Hasegawa et al. [46] provided evidence that the overexpression of miRNA-1246 is associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.

Studies performed on the expression of various types of miR-200, classified with tumor suppressor miRNAs, demonstrated that these miRNAs can regulate cell maintenance and EMT (by reducing levels of EMT markers) of PCSCs [40].

It has been reported that DCLK1 (a putative marker for pancreatic and intestinal cancer stem cells) regulates EMT in human pancreatic cancer cells through a mechanism dependent on miR-200a [41]. In this paper, the authors demonstrated that DCAMKL-1 expression was upregulated in human pancreatic adenocarcinoma tissue and in a KRAS transgenic mouse model of pancreatic cancer.

Experimental research proved that Zinc finger E-box binding homeobox 1 (ZEB1) is a crucial EMT promoter and inhibits expression of the microRNA-200 (miR-200) family and miR-203, resulting in the maintenance of stemness and EMT activation in colorectal and pancreatic cancer [42].

Pancreatic cancer cell growth can be inhibited also by a complex mechanism of regulation mediated by two tumor suppressor miRNAs, miR-143 and miR-145. Pramanik et al. [45] demonstrated that restoration of miR-143/145 levels, using a systemic nanovector, is able to inhibit pancreatic cancer cell growth in mice. This process seems to be mediated by a negative feedback loop in KRAS/RREB1-miR-143/145. The regulatory functions of miRNAs on the biological properties of PCSs are summarized in Table 2.

Table 2.

The regulatory functions of miRNAs on PCSCs properties.

Upregulation of onco-miRNAs Downregulation of tumor suppressor miRNAs Potential targets Biological PCSCs behavior Reference
miR-21   PI3K/AKT Proliferation and chemoresistance [37–39]
  miR-200a/c n-cadherin, ZEB 1 EMT, stemness maintenance [40–42]
  miR-34 BCL2 Self-renewal [43, 44]
  miR-143/miR-145 Kras Cancer cell growth [45]
  miR-1246 CCNG2 Chemoresistance and stemness [46]
Open in a new tab

Deregulation of miRNAs is also associated with the renewal and the differentiation of stem cells into cancer stem cells, as reported by Garg et al. [98, 99]. Moreover, some important regulators of the stem cell pluripotency (such as Sox9 and Nanog) and miRNAs targets have been described by Ahmed et al. [100].

An experimental approach based on microarray analysis demonstrated a linkage between clusters of miRNAs and clusters of stem cell-associated miRNAs in cancer stem cells [101]. Bao et al. [102] demonstrated that metformin inhibits cell proliferation, migration, and invasion of drug resistant pancreatic cancer cells by attenuating CSC function. This process is mediated by deregulation of miRNAs (let-7a, let-7b, miR-26a, miR-101, miR-200b, and miR-200c) in pancreatic cancer cells.

Altogether, these data suggest that a better comprehension of the regulatory feedback loop between miRNAs and CSC in pancreatic cancer could lead to the development of novel strategies in the treatment of pancreatic cancer patients by CSCs elimination.

6. Conclusions

Emerging data summarized in this review showed that miRNAs can function as oncogenes or tumor suppressors, playing important roles in the modulation of several biological activities of PCSCs. Despite these encouraging results, more studies on the function of miRNAs in PCSC biology will be needed in the future in order to improve pancreatic cancer treatments by using miRNAs, as innovative approach.

Acknowledgments

The authors thank Massimiliano Spinelli, for kindly helping in providing informatics assistance. This work was supported by current research programs of National Institute of Tumors, IRCCS “Foundation G. Pascale,” Naples (Italy).

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Sabrina Bimonte and Antonio Barbieri contributed equally to this paper.

References

  • 1.Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer Journal for Clinicians. 2014;64(1):9–29. doi: 10.3322/caac.21208. [DOI] [PubMed] [Google Scholar]
  • 2.Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treatment Reviews. 2014;40(9):1039–1047. doi: 10.1016/j.ctrv.2014.07.003. [DOI] [PubMed] [Google Scholar]
  • 3.Ferlay J., Parkin D. M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer. 2010;46(4):765–781. doi: 10.1016/j.ejca.2009.12.014. [DOI] [PubMed] [Google Scholar]
  • 4.Krejs G. J. Pancreatic cancer: epidemiology and risk factors. Digestive Diseases. 2010;28(2):355–358. doi: 10.1159/000319414. [DOI] [PubMed] [Google Scholar]
  • 5.Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011;364(19):1817–1825. doi: 10.1056/nejmoa1011923. [DOI] [PubMed] [Google Scholar]
  • 6.Cunningham D., Chau I., Stocken D. D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 2009;27(33):5513–5518. doi: 10.1200/JCO.2009.24.2446. [DOI] [PubMed] [Google Scholar]
  • 7.Burris H. A., III, Moore M. J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. 1997;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
  • 8.Oettle H., Lehmann T. Gemcitabine-resistant pancreatic cancer: a second-line option. The Lancet. 2015 doi: 10.1016/s0140-6736(15)01035-1. [DOI] [PubMed] [Google Scholar]
  • 9.Tang S.-N., Fu J., Shankar S., Srivastava R. K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS ONE. 2012;7(2) doi: 10.1371/journal.pone.0031067.e31067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Giovannetti E., Leon L. G., Bertini S., et al. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides, Nucleotides & Nucleic Acids. 2010;29(4–6):419–426. doi: 10.1080/15257771003730193. [DOI] [PubMed] [Google Scholar]
  • 11.Jaidev L. R., Krishnan U. M., Sethuraman S. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. Materials Science and Engineering C: Materials for Biological Applications. 2015;47:40–47. doi: 10.1016/j.msec.2014.11.027. [DOI] [PubMed] [Google Scholar]
  • 12.Leclerc E., Vetter S. W. The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochimica et Biophysica Acta. 2015;1852(12):2706–2711. doi: 10.1016/j.bbadis.2015.09.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhu Y. Y., Yuan Z. Pancreatic cancer stem cells. American Journal of Cancer Research. 2015;5(3):894–906. [PMC free article] [PubMed] [Google Scholar]
  • 14.Tanaka S. Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers. Journal of Hepato-Biliary-Pancreatic Sciences. 2015;22(7):531–537. doi: 10.1002/jhbp.248. [DOI] [PubMed] [Google Scholar]
  • 15.Bonnet D., Dick J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;3(7):730–737. doi: 10.1038/nm0797-730. [DOI] [PubMed] [Google Scholar]
  • 16.Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–648. doi: 10.1038/367645a0. [DOI] [PubMed] [Google Scholar]
  • 17.Hermann P. C., Huber S. L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–323. doi: 10.1016/j.stem.2007.06.002. [DOI] [PubMed] [Google Scholar]
  • 18.Van den Broeck A., Vankelecom H., Van Delm W., et al. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PLoS ONE. 2013;8(9) doi: 10.1371/journal.pone.0073968.e73968 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kopp J. L., Sander M. New insights into the cell lineage of pancreatic ductal adenocarcinoma: evidence for tumor stem cells in premalignant lesions? Gastroenterology. 2014;146(1):24–26. doi: 10.1053/j.gastro.2013.11.023. [DOI] [PubMed] [Google Scholar]
  • 20.Clarke M. F., Dick J. E., Dirks P. B., et al. Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Research. 2006;66(19):9339–9344. doi: 10.1158/0008-5472.can-06-3126. [DOI] [PubMed] [Google Scholar]
  • 21.Lee C. J., Dosch J., Simeone D. M. Pancreatic cancer stem cells. Journal of Clinical Oncology. 2008;26(17):2806–2812. doi: 10.1200/JCO.2008.16.6702. [DOI] [PubMed] [Google Scholar]
  • 22.Li C., Heidt D. G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Research. 2007;67(3):1030–1037. doi: 10.1158/0008-5472.CAN-06-2030. [DOI] [PubMed] [Google Scholar]
  • 23.Visvader J. E., Lindeman G. J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–728. doi: 10.1016/j.stem.2012.05.007. [DOI] [PubMed] [Google Scholar]
  • 24.Fessler E., Dijkgraaf F. E., De Sousa E Melo F., Medema J. P. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Letters. 2013;341(1):97–104. doi: 10.1016/j.canlet.2012.10.015. [DOI] [PubMed] [Google Scholar]
  • 25.Wang X., Zhu Y., Ma Y., et al. The role of cancer stem cells in cancer metastasis: new perspective and progress. Cancer Epidemiology. 2013;37(1):60–63. doi: 10.1016/j.canep.2012.07.007. [DOI] [PubMed] [Google Scholar]
  • 26.Castellanos J. A., Merchant N. B., Nagathihalli N. S. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. OncoTargets and Therapy. 2013;6:1261–1267. doi: 10.2147/ott.s34670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Xia J., Chen C., Chen Z., Miele L., Sarkar F. H., Wang Z. Targeting pancreatic cancer stem cells for cancer therapy. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer. 2012;1826(2):385–399. doi: 10.1016/j.bbcan.2012.06.002. [DOI] [PubMed] [Google Scholar]
  • 28.Sarkar F. H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resistance Updates. 2010;13(3):57–66. doi: 10.1016/j.drup.2010.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Danquah M., Singh S., Behrman S. W., Mahato R. I. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opinion on Drug Delivery. 2012;9(12):1443–1447. doi: 10.1517/17425247.2012.722079. [DOI] [PubMed] [Google Scholar]
  • 30.Kadera B. E., Li L., Toste P. A., et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS ONE. 2013;8(8) doi: 10.1371/journal.pone.0071978.e71978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sun L., Chua C. Y. X., Tian W., Zhang Z., Chiao P. J., Zhang W. MicroRNA signaling pathway network in pancreatic ductal adenocarcinoma. Journal of Genetics and Genomics. 2015;42(10):563–577. doi: 10.1016/j.jgg.2015.07.003. [DOI] [PubMed] [Google Scholar]
  • 32.Onishi H., Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World Journal of Gastroenterology. 2014;20(9):2335–2342. doi: 10.3748/wjg.v20.i9.2335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Xie J., Bartels C. M., Barton S. W., Gu D. Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets and Therapy. 2013;6:1425–1435. doi: 10.2147/ott.s34678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Abel E. V., Kim E. J., Wu J., et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE. 2014;9(3) doi: 10.1371/journal.pone.0091983.e91983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lonardo E., Hermann P. C., Mueller M.-T., et al. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9(5):433–446. doi: 10.1016/j.stem.2011.10.001. [DOI] [PubMed] [Google Scholar]
  • 36.Hage C., Rausch V., Giese N., et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death & Disease. 2013;4, article e627 doi: 10.1038/cddis.2013.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. Journal of Gastrointestinal Surgery. 2008;12(12):2171–2176. doi: 10.1007/s11605-008-0584-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Moriyama T., Ohuchida K., Mizumoto K., et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular Cancer Therapeutics. 2009;8(5):1067–1074. doi: 10.1158/1535-7163.MCT-08-0592. [DOI] [PubMed] [Google Scholar]
  • 39.Liu S., Patel S. H., Ginestier C., et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genetics. 2012;8(6) doi: 10.1371/journal.pgen.1002751.e1002751 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lu Y., Lu J., Li X., et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer. 2014;14, article 85 doi: 10.1186/1471-2407-14-85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Sureban S. M., May R., Lightfoot S. A., et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Research. 2011;71(6):2328–2338. doi: 10.1158/0008-5472.can-10-2738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wellner U., Schubert J., Burk U. C., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology. 2009;11(12):1487–1495. doi: 10.1038/ncb1998. [DOI] [PubMed] [Google Scholar]
  • 43.Ji Q., Hao X., Zhang M., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE. 2009;4(8) doi: 10.1371/journal.pone.0006816.e6816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Agostini M., Knight R. A. miR-34: from bench to bedside. Oncotarget. 2014;5(4):872–881. doi: 10.18632/oncotarget.1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Pramanik D., Campbell N. R., Karikari C., et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Molecular Cancer Therapeutics. 2011;10(8):1470–1480. doi: 10.1158/1535-7163.MCT-11-0152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hasegawa S., Eguchi H., Nagano H., et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. British Journal of Cancer. 2014;111(8):1572–1580. doi: 10.1038/bjc.2014.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Abel E. V., Simeone D. M. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology. 2013;144(6):1241–1248. doi: 10.1053/j.gastro.2013.01.072. [DOI] [PubMed] [Google Scholar]
  • 48.Michieli P., Mazzone M., Basilico C., et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004;6(1):61–73. doi: 10.1016/j.ccr.2004.05.032. [DOI] [PubMed] [Google Scholar]
  • 49.Herreros-Villanueva M., Zubia-Olascoaga A., Bujanda L. c-Met in pancreatic cancer stem cells: therapeutic implications. World Journal of Gastroenterology. 2012;18(38):5321–5323. doi: 10.3748/wjg.v18.i38.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Delitto D., Vertes-George E., Hughes S. J., Behrns K. E., Trevino J. G. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World Journal of Gastroenterology. 2014;20(26):8458–8470. doi: 10.3748/wjg.v20.i26.8458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Li C., Wu J., Hynes M., et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141(6):2218.e5–2227.e5. doi: 10.1053/j.gastro.2011.08.009. [DOI] [PubMed] [Google Scholar]
  • 52.Kim M. P., Fleming J. B., Wang H., et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE. 2011;6(6) doi: 10.1371/journal.pone.0020636.e20636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Kahlert C., Bergmann F., Beck J., et al. Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 2011;11, article 275 doi: 10.1186/1471-2407-11-275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Duong H.-Q., Hwang J. S., Kim H. J., Kang H. J., Seong Y.-S., Bae I. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. International Journal of Oncology. 2012;41(3):855–861. doi: 10.3892/ijo.2012.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.O'Connor M. L., Xiang D., Shigdar S., et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Letters. 2014;344(2):180–187. doi: 10.1016/j.canlet.2013.11.012. [DOI] [PubMed] [Google Scholar]
  • 56.Proctor E., Waghray M., Lee C. J., et al. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS ONE. 2013;8(2) doi: 10.1371/journal.pone.0055820.e55820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Cohen M. M., Jr. The hedgehog signaling network. American Journal of Medical Genetics Part A. 2003;123(1):5–28. doi: 10.1002/ajmg.a.20495. [DOI] [PubMed] [Google Scholar]
  • 58.Li K., Lv X.-X., Hua F., et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll-like receptor 2-mediated cell-penetrating peptide. International Journal of Cancer. 2014;134(3):692–702. doi: 10.1002/ijc.28382. [DOI] [PubMed] [Google Scholar]
  • 59.Tang S.-N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R. K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. International Journal of Cancer. 2012;131(1):30–40. doi: 10.1002/ijc.26323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Chen Y.-J., Huang Y.-C., Tsai T.-H., Liao H.-F. Effect of wasabi component 6-(methylsulfinyl)hexyl isothiocyanate and derivatives on human pancreatic cancer cells. Evidence-Based Complementary and Alternative Medicine. 2014;2014:6. doi: 10.1155/2014/494739.494739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Han J.-B., Sang F., Chang J.-J., et al. Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli. OncoTargets and Therapy. 2013;6:1129–1138. doi: 10.2147/ott.s49148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hebrok M. Hedgehog signaling in pancreas development. Mechanisms of Development. 2003;120(1):45–57. doi: 10.1016/S0925-4773(02)00331-3. [DOI] [PubMed] [Google Scholar]
  • 63.Rodova M., Fu J., Watkins D. N., Srivastava R. K., Shankar S. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS ONE. 2012;7(9) doi: 10.1371/journal.pone.0046083.e46083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Apelqvist Å., Li H., Sommer L., et al. Notch signalling controls pancreatic cell differentiation. Nature. 1999;400(6747):877–881. doi: 10.1038/23716. [DOI] [PubMed] [Google Scholar]
  • 65.Bao B., Wang Z., Ali S., et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Letters. 2011;307(1):26–36. doi: 10.1016/j.canlet.2011.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 66.Stemmer V., De Craene B., Berx G., Behrens J. Snail promotes Wnt target gene expression and interacts with β-catenin. Oncogene. 2008;27(37):5075–5080. doi: 10.1038/onc.2008.140. [DOI] [PubMed] [Google Scholar]
  • 67.Matsubara S., Ding Q., Miyazaki Y., Kuwahata T., Tsukasa K., Takao S. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Scientific Reports. 2013;3, article 3230 doi: 10.1038/srep03230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sun L., Mathews L. A., Cabarcas S. M., et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. STEM CELLS. 2013;31(8):1454–1466. doi: 10.1002/stem.1394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Iorio M. V., Croce C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Molecular Medicine. 2012;4(3):143–159. doi: 10.1002/emmm.201100209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Lee Y., Ahn C., Han J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415–419. doi: 10.1038/nature01957. [DOI] [PubMed] [Google Scholar]
  • 71.Bohnsack M. T., Czaplinski K., Görlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004;10(2):185–191. doi: 10.1261/rna.5167604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Yi R., Qin Y., Macara I. G., Cullen B. R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & Development. 2003;17(24):3011–3016. doi: 10.1101/gad.1158803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Lund E., Güttinger S., Calado A., Dahlberg J. E., Kutay U. Nuclear export of microRNA precursors. Science. 2004;303(5654):95–98. doi: 10.1126/science.1090599. [DOI] [PubMed] [Google Scholar]
  • 74.Ketting R. F., Fischer S. E. J., Bernstein E., Sijen T., Hannon G. J., Plasterk R. H. A. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans . Genes and Development. 2001;15(20):2654–2659. doi: 10.1101/gad.927801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Bernstein E., Kim S. Y., Carmell M. A., et al. Dicer is essential for mouse development. Nature Genetics. 2003;35(3):215–217. doi: 10.1038/ng1253. [DOI] [PubMed] [Google Scholar]
  • 76.Hutvágner G., McLachlan J., Pasquinelli A. E., Bálint É., Tuschl T., Zamore P. D. A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293(5531):834–838. doi: 10.1126/science.1062961. [DOI] [PubMed] [Google Scholar]
  • 77.Knight S. W., Bass B. L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans . Science. 2001;293(5538):2269–2271. doi: 10.1126/science.1062039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Uchino K., Takeshita F., Takahashi R.-U., et al. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Molecular Therapy. 2013;21(3):610–619. doi: 10.1038/mt.2012.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Yang X., Du W. W., Li H., et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Research. 2013;41(21):9688–9704. doi: 10.1093/nar/gkt680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Pasquinelli A. E., Reinhart B. J., Slack F., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86–89. doi: 10.1038/35040556. [DOI] [PubMed] [Google Scholar]
  • 81.Lee R. C., Feinbaum R. L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854. doi: 10.1016/0092-8674(93)90529-y. [DOI] [PubMed] [Google Scholar]
  • 82.John B., Enright A. J., Aravin A., Tuschl T., Sander C., Marks D. S. Human microRNA targets. PLoS Biology. 2004;2(11, article e363) doi: 10.1371/journal.pbio.0020363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Friedman R. C., Farh K. K.-H., Burge C. B., Bartel D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research. 2009;19(1):92–105. doi: 10.1101/gr.082701.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Ørom U. A., Nielsen F. C., Lund A. H. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Molecular Cell. 2008;30(4):460–471. doi: 10.1016/j.molcel.2008.05.001. [DOI] [PubMed] [Google Scholar]
  • 85.Mandke P., Wyatt N., Fraser J., Bates B., Berberich S. J., Markey M. P. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS ONE. 2012;7(8) doi: 10.1371/journal.pone.0042034.e42034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Leal J. A., Lleonart M. E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Letters. 2013;338(1):174–183. doi: 10.1016/j.canlet.2012.04.020. [DOI] [PubMed] [Google Scholar]
  • 87.Ceppi P., Peter M. E. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene. 2014;33(3):269–278. doi: 10.1038/onc.2013.55. [DOI] [PubMed] [Google Scholar]
  • 88.Rosanò L., Spinella F., Di Castro V., et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Research. 2005;65(24):11649–11657. doi: 10.1158/0008-5472.CAN-05-2123. [DOI] [PubMed] [Google Scholar]
  • 89.Shi Y., Liu C., Liu X., Tang D. G., Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS ONE. 2014;9(3) doi: 10.1371/journal.pone.0090022.e90022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Zhang B., Pan X., Cobb G. P., Anderson T. A. microRNAs as oncogenes and tumor suppressors. Developmental Biology. 2007;302(1):1–12. doi: 10.1016/j.ydbio.2006.08.028. [DOI] [PubMed] [Google Scholar]
  • 91.Lynam-Lennon N., Maher S. G., Reynolds J. V. The roles of microRNA in cancer and apoptosis. Biological Reviews. 2009;84(1):55–71. doi: 10.1111/j.1469-185X.2008.00061.x. [DOI] [PubMed] [Google Scholar]
  • 92.Kent O. A., Mendell J. T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–6196. doi: 10.1038/sj.onc.1209913. [DOI] [PubMed] [Google Scholar]
  • 93.Zhan H.-X., Xu J.-W., Wu D., Zhang T.-P., Hu S.-Y. Pancreatic cancer stem cells: new insight into a stubborn disease. Cancer Letters. 2015;357(2):429–437. doi: 10.1016/j.canlet.2014.12.004. [DOI] [PubMed] [Google Scholar]
  • 94.Ma C., Huang T., Ding Y. C., Yu W., Wang Q., Meng B., et al. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells. International Journal of Clinical and Experimental Pathology. 2015;8(6):6533–6539. [PMC free article] [PubMed] [Google Scholar]
  • 95.Albulescu R., Neagu M., Albulescu L., Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Review of Molecular Diagnostics. 2011;11(1):101–120. doi: 10.1586/erm.10.106. [DOI] [PubMed] [Google Scholar]
  • 96.Haselmann V., Kurz A., Bertsch U., et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology. 2014;146(1):278–290. doi: 10.1053/j.gastro.2013.10.009. [DOI] [PubMed] [Google Scholar]
  • 97.Giovannetti E., Funel N., Peters G. J., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Research. 2010;70(11):4528–4538. doi: 10.1158/0008-5472.can-09-4467. [DOI] [PubMed] [Google Scholar]
  • 98.Garg M. MicroRNAs, stem cells and cancer stem cells. World Journal of Stem Cells. 2012;4(7):62–70. doi: 10.4252/wjsc.v4.i7.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Navarro A., Monzó M. MicroRNAs in human embryonic and cancer stem cells. Yonsei Medical Journal. 2010;51(5):622–632. doi: 10.3349/ymj.2010.51.5.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Ahmed A., Specht C., Lowden M. R. A patient with confusion and dizziness. Journal of Clinical Neuroscience. 2012;19(9):p. 1281. doi: 10.1016/j.jocn.2011.07.037. [DOI] [PubMed] [Google Scholar]
  • 101.Jung D. E., Wen J., Oh T., Song S. Y. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas. 2011;40(8):1180–1187. doi: 10.1097/mpa.0b013e318221b33e. [DOI] [PubMed] [Google Scholar]
  • 102.Bao B., Wang Z., Ali S., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevention Research. 2012;5(3):355–364. doi: 10.1158/1940-6207.CAPR-11-0299. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Stem Cells International are provided here courtesy of Wiley

RESOURCES